Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of PQR309 in relapsed or refractory primary CNS lymphoma
2015-001306-33Phase 2Terminated
- Sponsor
- PIQUR Therapeutics AG
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimiralisib in primary central nervous system lymphoma (PCNSL), sponsored by PIQUR Therapeutics AG. Primary endpoint: Overall response rate. Started Jan 2017; status: terminated.
02
Drugs
bimiralisib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2015-001306-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001306-33.